Zurich Cantonal Bank’s Akebia Therapeutics AKBA Stock Holding History

Zurich Cantonal Bank’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-55,473	Closed	-$116K	–	2571
2025 Q3	$151K	Buy	+55,473	New	+$185K	﹤0.01%	2296
2022 Q2	–	Sell	-15,482	Closed	-$11K	–	2890
2022 Q1	$11K	Hold	15,482	–	–	﹤0.01%	2700
2021 Q4	$35K	Hold	15,482	–	–	﹤0.01%	2805
2021 Q3	$45K	Hold	15,482	–	–	﹤0.01%	2643
2021 Q2	$59K	Hold	15,482	–	–	﹤0.01%	2413
2021 Q1	$52K	Hold	15,482	–	–	﹤0.01%	2370
2020 Q4	$43K	Hold	15,482	–	–	﹤0.01%	2468
2020 Q3	$39K	Hold	15,482	–	–	﹤0.01%	2323
2020 Q2	$210K	Buy	15,482 +9,703	+168%	+$100K	﹤0.01%	1483
2020 Q1	$44K	Hold	5,779	–	–	﹤0.01%	1988
2019 Q4	$37K	Hold	5,779	–	–	﹤0.01%	2293
2019 Q3	$23K	Hold	5,779	–	–	﹤0.01%	2405
2019 Q2	$28K	Hold	5,779	–	–	﹤0.01%	2345
2019 Q1	$47K	Sell	5,779 -2,033	-26%	-$14K	﹤0.01%	2043
2018 Q4	$43K	Buy	7,812 +2,835	+57%	+$22.2K	﹤0.01%	2117
2018 Q3	$44K	Hold	4,977	–	–	﹤0.01%	2219
2018 Q2	$50K	Buy	4,977 +2,876	+137%	+$28.8K	﹤0.01%	2124
2018 Q1	$20K	Buy	+2,101	New	+$29.4K	﹤0.01%	2410

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Zurich Cantonal Bank's AKBA Position: Q4 2025 in Review

Zurich Cantonal Bank sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 55,473 shares — an estimated $116K sold.

Zurich Cantonal Bank first reported a position in AKBA in Q1 2018 and held it in 18 quarters. The position peaked at $210K in Q2 2020. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Zurich Cantonal Bank reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Zurich Cantonal Bank sold 55,473 Akebia Therapeutics shares in Q4 2025, an estimated $116K.
Zurich Cantonal Bank first reported a position in Akebia Therapeutics in Q1 2018 and held it in 18 quarters.
Zurich Cantonal Bank's Akebia Therapeutics position peaked at $210K in Q2 2020.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Zurich Cantonal Bank's 13F filing for Q4 2025, filed 27 Jan 2026.